Study of Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

NCT02132390 Phase 3 UNKNOWN

Compare the potential benefits of adjuvant toremifene with or without goserelin in premenopausal women with stage I-IIIA, hormonal receptor positive breast cancer accompanied with or without chemotherapy induced amenorrhoea.

Details

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 3
Status	UNKNOWN
Enrolment	300
Start date	2014-05

Conditions

• Breast Cancer
• Chemotherapy Induced Amenorrhea
• Ovarian Function Suppression

Interventions

• Goserelin
• Toremifene

Primary outcomes

• Disease free survival — up to 120 months
• Overall Survival — up to 120 months

Countries

China